拉貝珠單抗

化合物

拉貝珠單抗INN:labetuzumab;商品名CEA-CIDE)是一種人源化IgG1單株抗體,用於治療結直腸癌[1]它選擇性地結合CEACAM5英語CEACAM5[2]

拉貝珠單抗
單株抗體
種類完整抗體
目標癌胚抗原
臨床資料
ATC碼
  • 未分配
識別資訊
CAS號219649-07-7  checkY
ChemSpider
  • none
UNII
KEGG

該藥物還被用在患有轉移的甲狀腺髓樣癌患者中進行了測試。[3]

該藥物由Immunomedics英語Immunomedics開發。

參考資料

  1. ^ International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab (PDF). WHO Drug Information. 2002, 16 (1): 95 [2024-03-13]. (原始內容存檔 (PDF)於2024-07-31). 
  2. ^ labetuzumab-SN-38 immunoconjugate IMMU-130. National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services. [2024-03-13]. (原始內容存檔於2015-05-11). 
  3. ^ Stein, Rhona; Goldenberg, David M. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Molecular Cancer Therapeutics. 2004-12, 3 (12) [2024-03-13]. ISSN 1535-7163. PMID 15634649. (原始內容存檔於2024-03-13).